Buprenorphine

Buprenorphine is an opioid partial agonist that is effective for many in the treatment of opioid use disorder (OUD). Similarly to methadone, buprenorphine is a controlled substance and has the potential for misuse and diversion. However, unlike methadone, it is less likely to lead to overdose unless combined with other sedatives.

Related Training Resources

Presenter(s):
Adam Fussaro, LSW, LCSW, and Kristina Scalia-Jackson, BA
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
According to the Centers for Disease Control (CDC), more than 111,000 people died from a drug overdose in the 12-month period ending last September. Unhoused individuals are especially at risk of overdose deaths. Recent studies show that of people experiencing homelessness, drug-overdose accounted for 1 in 4 deaths. As drug-related overdose deaths continue to rise, the need for innovative, early intervention and harm-reducing services are especially relevant. Programs across the country have begun to develop strategies to reduce harm in these at-risk populations. Come join us as we profile one such program that is focused on providing life-saving medications and interventions to unhoused populations.
Is it appropriate to prescribe buprenorphine monoproduct on a case-by-case basis for the treatment of Opioid Use Disorder for management of patients who experience adverse effects from buprenorphine/naloxone (bup/nx; Suboxone, Zubsolv)?
Presenter(s):
Ed Hayes: Assistant Superintendent at Franklin County Sheriff’s Office, Administrative Director of the FCSO OTP and Rachel Katz, NP Director, Addiction Services, Friends of the Homeless (FOH), Medical Respite, CNP
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Transitioning from jails and prisons back into the community can be especially difficult for people with opioid use disorders (OUD). Research suggests that opioid use overdose increases dramatically within the first 30 days of citizens returning to the community. Further, individuals recently released from incarceration face a risk of opioid overdose ten times greater than the general public. During these transitions it is critical that people receive seamless and appropriate resources in order to prevent overdose and return to use. This proper transition can help lower health care costs, hospitalizations and emergency department visits, as well as decrease mortality and recidivism for justice-involved individuals, yet at this time only 13 states have sought Medicaid waivers to provide SUD services pre-release. Join us today as we explore how programs can successfully develop services to ensure returning citizens receive appropriate care to address OUD.
Presenter(s):
Bobby Mukkamala, MD and Elizabeth Salisbury-Afshar, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit
Opioid use disorder is a chronic disease that affects many and can be effectively treated. Evidence-based treatment for opioid use disorder (OUD), as well as harm reduction initiatives, can help individuals maintain in treatment and mitigate risks of relapse. In this episode, we’ll discuss medications for opioid use disorder (MOUD) as well as OUD treatment considerations and standards of care. The discussion will also include barriers that can stand in the way of those seeking treatment.
Oral health is an essential part of overall health. Healthcare professionals who provide care to patients with possible Opioid Use Disorder (OUD) or Substance Use Disorders (SUD) need to be aware of the special considerations this population may experience. Use this resource to learn how dental professionals can identify patients who may be at high-risk for OUD and SUD, while seeking care in the dental setting.
Psychiatric pharmacists are advanced practice clinical pharmacists committed to being part of an interdisciplinary team treating substance use disorders, often in combination with serious mental illness. The following SUD toolkits were developed to further the knowledge of pharmacists and other healthcare professionals.
Presenter(s):
Sachin Kale, MD; and Justin Kullgren, PharmD, FAAHPM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit
In this talk, we will discuss the creation of the Palliative Ham Reduction and Resiliency Clinic at The Ohio State Wexner Medical Center. This is a Palliative Medicine clinic with additional resources and support for patients with concurrent SUDs—including additional psycho-social support, substance use evaluation and management, and coordination of care. We provide care for patients with active cancer and concurrent substance misuse. We will discuss implementing a culture of (1) patient-centeredness, (2) safety, (3) collaboration, and (4) addiction support into our clinic model. We will also discuss our philosophy on safer opioid prescribing and harm reduction.
In 2022, the CDC estimated over 107,000 American deaths related to drug overdose as the pandemic spreads nationwide, surpassing the toll of gun violence and car accidents combined. The widespread use of Fentanyl fueled the rise in fatalities. As the pandemic worsens, it is important to understand its impact on our communities and healthcare workers, keeping ourselves safe with proper knowledge of drugs and the ever-changing environment.
Presenter(s):
Danae DiRocco, MD, MPH; Chun Tong, MD; and Yngvild K. Olsen, MD, MPH
Credit Available:
CE Credit(s): No
Certificate: No
A new law soon goes into effect that requires new or renewing DEA licensees, as of June 27, 2023, to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain. Dr Yngvild Olsen, director of the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration, joins AAAP to discuss the requirements going into effect, what should clinicians know about the changes, and how to best prepare.
Presenter(s):
Mark Parrino, President & CEO of The American Association for the Treatment of Opioid Dependence, Inc. and Jennifer Seib, VP of Strategic Initiatives and Integration at BestSelf Behavioral Health
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
The current opioid and drug overdose crisis continues to have a devastating impact on morbidity and mortality in the United States. With the rise in use of potent synthetic opioids like fentanyl in the drug supply, creating linkages to comprehensive substance use related services is critical. Opioid Treatment Programs (OTP) and the comprehensive care and services they provide play a vital role in addressing this need, yet challenges remain. Despite clear evidence of the benefits of OTP’s, access to OTPs in some parts of the country is limited; stigma related to the use of methadone remains a challenge. Yet in the face of these headwinds, many OTPs are providing comprehensive leading-edge services to address the opioid and drug overdose crisis.
Loading more
2018 Steering Committee Meeting

Buprenorphine Training

PCSS-MOUD offers free buprenorphine training to learn about prescribing medication for the treatment of opioid use disorder.

Buprenorphine Quick Start Guide​

SAMHSA has developed a Buprenorphine Quick Start Guide for practitioners looking to prescribe buprenorphine.